Skip to main content
Atrás
Watch Compare

Marker Therapeutics, Inc.

Calidad de datos: 83%
MRKR
Nasdaq Manufacturing Chemicals
$1.75
$0.00 (0.00%)
Cap. Mercado: 22.64 M
Precio
$1.75
Cap. Mercado
22.64 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Negative free cash flow of -12.01 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-84.24%
Below sector avg (-53.47%)
ROIC-70.52%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio6.50
Interest CoverageN/A

Valoración

PE (TTM)
-1.86
Below sector avg (-1.48)
P/B Ratio1.23
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -1.9 -1.5
P/B 1.2 1.6
ROE % -84.2 -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Precio Objetivo de Analistas

3 analistas
Buy
Actual
$1.75
+349.5%
Objetivo
$7.87
$5.60
$8.00
$10.00
Pronóstico
P/E Futuro -9.21
EPS Futuro -$0.19
Ingresos Est. 20.05 M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$0.19
-$0.19 – -$0.19
 20.05 M 1
FY2026 -$0.61
-$0.61 – -$0.61
 2.70 M 1

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.19 -$0.04 +79.0%
Q32025 -$0.21 -$0.12 +42.9%
Q22025 -$0.27 -$0.29 -7.4%
Q12025 -$0.66 -$0.40 +39.4%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -12.16 M
ROE -84.24% ROA -66.65%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12.01 M
ROIC -70.52% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 6.50
Interest Coverage N/A Asset Turnover N/A
Working Capital 18.39 M Tangible Book Value 18.39 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.86 Forward P/E N/A
P/B Ratio 1.23 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -53.06%
Market Cap 22.64 M Enterprise Value 5.05 M
Per Share
EPS (Diluted TTM) -0.79 Revenue / Share N/A
FCF / Share -0.93 OCF / Share -0.93
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 98.77%
SBC-Adj. FCF -12.49 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — 0.0
Net Income -12.16 M -10.73 M -8.24 M -29.93 M -41.88 M
EPS (Diluted) -0.79 -1.19 -0.94 -3.58 -0.55
Gross Profit — — — — —
Operating Income -12.89 M -11.12 M -14.58 M -29.95 M -39.48 M
EBITDA — — — — —
R&D Expenses 11.80 M 13.47 M 10.42 M 26.14 M 27.79 M
SG&A Expenses — — — — —
D&A — — — 2.79 M 2.15 M
Interest Expense — — — — —
Income Tax -15,156.0 49,953.0 3,675.0 — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19.07 M 22.02 M 17.13 M 34.42 M 68.14 M
Total Liabilities 2.27 M 3.46 M 3.07 M 14.82 M 24.15 M
Shareholders' Equity 16.80 M 18.56 M 14.05 M 19.60 M 43.99 M
Total Debt — — — — —
Cash & Equivalents 16.07 M 19.19 M 15.11 M 11.78 M 42.35 M
Current Assets 19.07 M 22.02 M 17.13 M 16.62 M 45.98 M
Current Liabilities 2.27 M 3.46 M 3.07 M 7.78 M 12.90 M